PCRX Stock Analysis: Pacira BioSciences | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 984m USD | 12M Return: -2.1% | US6951271005 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.4M
EPS Trend: -64.4%
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pacira BioSciences is a U.S.-based specialty pharmaceutical company focused on non-opioid pain management and regenerative health solutions for healthcare practitioners. Its commercial portfolio centers on EXPAREL, a long-acting local anesthetic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and the iovera cryoanalgesia system, which uses controlled cold to block peripheral nerve pain signals.
The company is also advancing PCRX-201, an intra-articular gene therapy candidate for osteoarthritis, and maintains a veterinary partnership with Aratana Therapeutics for NOCITA, a bupivacaine liposome injectable for animal use. The business model combines proprietary drug delivery platforms (notably multivesicular liposome technology used in EXPAREL) with device-based interventions, positioning Pacira within the broader effort to reduce reliance on opioid-based pain therapies in both human and animal health markets.
Originally incorporated in 2006 as Pacira Pharmaceuticals, the company rebranded as Pacira BioSciences in April 2019, reflecting its strategic expansion from specialty injectables into regenerative medicine and gene therapy. It is headquartered in Brisbane, California, and trades on NASDAQ under the ticker PCRX.
- EXPAREL postsurgical sales volume drives quarterly revenue growth
- ZILRETTA faces pricing pressure from generic steroids and reimbursement cuts
- PCRX-201 gene therapy pipeline advances for osteoarthritis treatment
| Net Income: 14.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 6.82 > 1.0 |
| NWC/Revenue: 66.10% < 20% (prev 61.27%; Δ 4.83% < -1%) |
| CFO/TA 0.15 > 3% & CFO 187.7m > Net Income 14.6m |
| Net Debt (210.1m) to EBITDA (114.8m): 1.83 < 3 |
| Current Ratio: 5.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.3m) vs 12m ago -11.35% < -2% |
| Gross Margin: 79.21% > 18% (prev 78.19%; Δ 1.01% > 0.5%) |
| Asset Turnover: 53.66% > 50% (prev 45.92%; Δ 7.74% > 0%) |
| Interest Coverage Ratio: 2.14 > 6 (EBIT TTM 29.6m / Interest Expense TTM 13.8m) |
| A: 0.40 (Total Current Assets 615.2m - Total Current Liabilities 122.0m) / Total Assets 1.24b |
| B: -0.15 (Retained Earnings -191.8m / Total Assets 1.24b) |
| C: 0.02 (EBIT TTM 29.6m / Avg Total Assets 1.39b) |
| D: 1.17 (Book Value of Equity 672.0m / Total Liabilities 572.0m) |
| Altman-Z'' = 3.47 = A |
| DSRI: 1.10 (Receivables 132.4m/114.4m, Revenue 746.2m/705.8m) |
| GMI: 0.99 (GM 78.19% / 79.21%) |
| AQI: 0.95 (AQ_t 0.36 / AQ_t-1 0.38) |
| SGI: 1.06 (Revenue 746.2m / 705.8m) |
| TATA: -0.14 (NI 14.6m - CFO 187.7m) / TA 1.24b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 25.12 with a total of 439,929 shares traded. Over the past week, the price has changed by +1.74%, over one month by -1.61%, over three months by +3.08% and over the past year by -2.07%.
Current recommended Stop Loss: 23.20 (which is 7.6% or 2.3 ATR below the current price).
Pacira BioSciences has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PCRX.
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 30 | 19.4% |
P/E Trailing = 70.5429
P/E Forward = 6.2189
P/S = 1.319
P/B = 1.4536
P/EG = 11.2121
Revenue TTM = 746.2m USD
EBIT TTM = 29.6m USD
EBITDA TTM = 114.8m USD
Long Term Debt = 363.1m USD (from longTermDebt, last quarter)
Short Term Debt = 10.3m USD (from shortTermDebt, last quarter)
Debt = 461.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 49.0m
Net Debt = 210.1m USD (calculated: Debt 461.1m - CCE 251.0m)
Enterprise Value = 1.19b USD (984.2m + Debt 461.1m - CCE 251.0m)
Interest Coverage Ratio = 2.14 (Ebit TTM 29.6m / Interest Expense TTM 13.8m)
EV/FCF = 6.65x (Enterprise Value 1.19b / FCF TTM 179.5m)
FCF Yield = 15.03% (FCF TTM 179.5m / Enterprise Value 1.19b)
FCF Margin = 24.06% (FCF TTM 179.5m / Revenue TTM 746.2m)
Net Margin = 1.96% (Net Income TTM 14.6m / Revenue TTM 746.2m)
Gross Margin = 79.21% ((Revenue TTM 746.2m - Cost of Revenue TTM 155.2m) / Revenue TTM)
Gross Margin QoQ = 77.05% (prev 79.47%)
Tobins Q-Ratio = 0.96 (Enterprise Value 1.19b / Total Assets 1.24b)
Interest Expense / Debt = 3.00% (Interest Expense 13.8m / Debt 461.1m)
Taxrate = 17.06% (3.01m / 17.6m)
NOPAT = 24.5m (EBIT 29.6m * (1 - 17.06%))
Current Ratio = 5.04 (Total Current Assets 615.2m / Total Current Liabilities 122.0m)
Debt / Equity = 0.69 (Debt 461.1m / totalStockholderEquity, last quarter 672.0m)
Debt / EBITDA = 1.83 (Net Debt 210.1m / EBITDA 114.8m)
Debt / FCF = 1.17 (Net Debt 210.1m / FCF TTM 179.5m)
Total Stockholder Equity = 686.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.05% (Net Income 14.6m / Total Assets 1.24b)
RoE = 2.13% (Net Income TTM 14.6m / Total Stockholder Equity 686.5m)
RoCE = 2.82% (EBIT 29.6m / Capital Employed (Equity 686.5m + L.T.Debt 363.1m))
RoIC = 2.24% (NOPAT 24.5m / Invested Capital 1.09b)
WACC = 4.98% (E(984.2m)/V(1.45b) * Re(6.15%) + D(461.1m)/V(1.45b) * Rd(3.00%) * (1-Tc(0.17)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.91 | Cagr: -10.86%
[DCF] Terminal Value 77.97% ; FCFF base≈154.5m ; Y1≈177.1m ; Y5≈260.7m
[DCF] Fair Price = 93.15 (EV 3.92b - Net Debt 210.1m = Equity 3.71b / Shares 39.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -64.36 | EPS CAGR: -9.86% | SUE: 1.26 | # QB: 1
Revenue Correlation: 98.99 | Revenue CAGR: 3.85% | SUE: 0.33 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.71 | Chg30d=-6.19% | Revisions=-12% | Analysts=7
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=+0.22% | Revisions=+0% | GrowthEPS=+8.8% | GrowthRev=+3.6%
EPS next Year (2027-12-31): EPS=3.45 | Chg30d=-5.42% | Revisions=-67% | GrowthEPS=+19.7% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -35% (up=5, down=12)